logo
Site Network

Menu

Source Legend
  • Human-provided

    Entered or confirmed by an authorized person.

  • Google

    Imported Google information.

  • Trial-derived

    Calculated or extracted directly from associated trial records.

  • AI-inferred

    A capability inferred from trial history.

  • AI-extracted

    An explicit statement extracted from an official source.

  • Public registry

    Information from a public registry.

  • Site record

    Information held in the site record.

Source: Site record. Velindre Cancer Centre

+442920615888
Source: Site record.
https://velindre.nhs.wales/velindrecc

Claim This Site

Are you the site administrator? Claim this site to update information.

Basic Information

Site Overview

Source: Google.

Velindre Cancer Centre is part of Velindre University University NHS Trust and provides specialist cancer services to 1.5 million people living in South East Wales. Velindre is one of the largest cancer centres in the UK. The Cancer Centre is a specialist treatment, teaching and research and development centre for non-surgical oncology, treating patients with chemotherapy, radiotherapy and related treatments, and caring for patients with specialist palliative care needs.

Business Status

Source: Google. OPEN

Business Category

Source: Google. Cancer treatment center

Business Subcategory

Source: Google. Cancer treatment center
Source: Trial-derived.
116Total Trials
Source: Trial-derived.
40Recruiting Trials
Source: Trial-derived.
63Active Trials
Source: Trial-derived.
44Completed Trials
Source: Trial-derived.
168Unique Conditions
Source: Trial-derived.
106Unique Sponsors

Conditions

Source: Trial-derived. Breast Cancer (8)Source: Trial-derived. Cancer (8)Source: Trial-derived. Haematological Malignancy (7)Source: Trial-derived. Solid Tumour (7)Source: Trial-derived. Colorectal Cancer (6)Source: Trial-derived. Neoplasms by Histologic Type (6)Source: Trial-derived. Neoplasms by Site (6)Source: Trial-derived. Prostate Cancer (6)

Sponsors

Source: Trial-derived. Hoffmann-La Roche (24)Source: Trial-derived. Cancer Research UK (23)Source: Trial-derived. University of Birmingham (13)Source: Trial-derived. Royal Marsden NHS Foundation Trust (12)Source: Trial-derived. BioNTech SE (10)Source: Trial-derived. University of Manchester (10)Source: Trial-derived. University College, London (9)Source: Trial-derived. Merck Sharp & Dohme LLC (8)

Facilities & Operations

Facilities and operational capabilities inferred from trial participation

Source: AI-inferred. Overnight or inpatient research stays supported

Imaging & Diagnostics

Imaging and diagnostic capabilities inferred from trial participation

Source: AI-inferred. Electrocardiography (lead count not stated)
Source: AI-inferred. 12-lead ECG
Source: AI-inferred. MRI

Laboratory & Biospecimens

Laboratory and biospecimen capabilities inferred from trial participation

Source: AI-inferred. Clinical laboratory testing
Source: AI-inferred. Specimen packaging and shipment
Source: AI-inferred. Timed pharmacokinetic sampling and processing
Source: AI-inferred. Histology / pathology
Source: AI-inferred. Immunogenicity (anti-drug antibody) testing
Source: AI-inferred. Pharmacokinetic bioanalysis

Research Pharmacy & Investigational Product

Investigational-product capabilities inferred from trial participation

Source: AI-inferred. Hazardous / cytotoxic drug handling

Clinical Procedures

Clinical procedures inferred from trial participation

Source: AI-inferred. Intravenous infusion administration

Accessibility & Parking

Accessibility Features

Source: Google. Wheelchair accessible entrance
Source: Google. Wheelchair accessible parking lot
Source: Google. Wheelchair accessible restroom

Amenities

Amenities Available

Source: Google. Restroom

Additional Capabilities

Other capabilities inferred from trial participation

Source: AI-inferred. BRAF V600E mutation testing
Source: AI-inferred. Left ventricular ejection fraction measurement
Source: AI-inferred. Ophthalmologic examination
Source: AI-inferred. PD-L1 expression testing
Source: AI-inferred. PIK3CA mutation testing of tumour tissue